Showing results (81-90 of 137) with videos related to
Sort By:
Pageof 14
Circulation|April 1, 1994
Tissue plasminogen activator, plasminogen activator inhibitor-1, and fibrin as indexes of clinical course in cardiac allograft recipients. An immunocytochemical studyC A Labarrere, D Pitts, H Halbrook, et al.The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|May 1, 1993
Immunoglobulin M antibodies in transplanted human heartsC A Labarrere, D Pitts, H Halbrook, et al.Transplantation|May 1, 1993
Tissue plasminogen activator in human cardiac allograftsC A Labarrere, D Pitts, H Halbrook, et al.Journal of Gambling Studies|March 29, 2018
Evidence of Skill and Strategy in Daily Fantasy BasketballBrent A Evans, Justin Roush, Joshua D Pitts, et al.The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|March 1, 1993
Laboratory-clinical correlates of time-associated lesions in the vascular immunopathology of human cardiac allograftsW P Faulk, C A Labarrere, D Pitts, et al.The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|March 1, 1993
Vascular lesions in biopsy specimens devoid of cellular infiltrates: qualitative and quantitative immunocytochemical studies of human cardiac allograftsW P Faulk, C A Labarrere, D Pitts, et al.The Journal of Arthroplasty|July 7, 2000
Are clinical and patient assessed outcomes affected by reducing length of hospital stay for total hip arthroplasty?J H Hayes, R Cleary, W J Gillespie, et al.The New England Journal of Medicine|October 26, 1995
Vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplant recipientsC A Labarrere, D Pitts, D R Nelson, et al.The EMBO Journal|January 1, 1983
Analysis of vertebrate gap junction proteinM E Finbow, J Shuttleworth, A E Hamilton, et al.Clinical Therapeutics|March 2, 2006
Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trialsDavid L Dunner, Alan Lipschitz, Cornelius D Pitts, et al.Pageof 14